Etirinotecan Pegol Benefits Patients with Advanced Breast Cancer
Etirinotecan pegol provided a clinically meaningful benefit to patients with late-stage advanced breast cancer.
Advanced Breast Cancer
Palbociclib, Fulvestrant Improves Progression-Free Survival in HR+, HER2- Breast Cancer
Palbociclib with fulvestrant improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer.
Classifying Breast Cancer Subtype May Improve Risk Stratification
Classifying breast cancers according to tumor subtypes could help improve treatment of the disease.
Diabetes May Predispose Women to More Advanced Breast Cancer
Women with diabetes may have an increased risk of being diagnosed with advanced breast cancer.
Shorter Progression-Free Survival with Lapatinib in Breast Cancer
Lapatinib is associated with shorter progression-free survival, more toxicity in patients with HER2-positive breast cancer compared with trastuzumab.
Many Women Not Receiving Recommended Radiation Therapy After Mastectomy
More than a third with locally-advanced breast cancer don’t get radiation therapy aimed at preventing tumor’s return.
BRCA1/2 and Other Breast Cancer Gene Mutations in Patients Unselected for Family History
How frequent are mutations in known breast cancer predisposition genes in women with TNBC who were unselected for family history?
Palbociclib Doubles Survival in Women with Advanced Breast Cancer
Palbociclib doubled progression-free survival (PFS) in women with ER-positive, HER2-positive advanced breast cancer.
Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
[Breast Cancer (Auckl)] Human epidermal growth factor receptor-2 is overexpressed in up to 30% of breast cancers; indicative of poor prognosis.
Screening for Breast Cancer in Elderly Women Questioned
Mammograms for those aged 69 to 75 could result in overtreatment, researchers caution.
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...